Oncopeptides (Sweden) Insiders
| ONCO Stock | SEK 1.52 0.03 1.94% |
Oncopeptides employs about 40 people. The company is managed by 8 executives with a total tenure of roughly 94 years, averaging almost 11.0 years of service per executive, having 5.0 employees per reported executive. Breaking down Oncopeptides' management performance can provide insight into the firm performance.
| Annika MBA Insider Interim Officer |
| Kristina Luthman Insider Founder |
Oncopeptides |
Oncopeptides Management Team Effectiveness
The company has return on total asset (ROA) of (0.6651) % which means that it has lost $0.6651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2916) %, meaning that it generated substantial loss on money invested by shareholders. Oncopeptides' management efficiency ratios could be used to measure how well Oncopeptides manages its routine affairs as well as how well it operates its assets and liabilities.Oncopeptides Workforce Comparison
Oncopeptides AB is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,854. Oncopeptides claims roughly 40.0 in number of employees contributing just under 2% to equities under Health Care industry.
Oncopeptides AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Oncopeptides AB Price Series Summation is a cross summation of Oncopeptides price series and its benchmark/peer.
Oncopeptides Notable Stakeholders
An Oncopeptides stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oncopeptides often face trade-offs trying to please all of them. Oncopeptides' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oncopeptides' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Annika MBA | Interim Officer | Profile | |
| Kristina Luthman | Founder | Profile | |
| Linda Holmstrom | Director Relations | Profile | |
| Peter Nygren | Founder | Profile | |
| Pr MD | Founder | Profile | |
| Jakob Lic | Chief Officer | Profile | |
| MSc MD | Founder | Profile | |
| MSc MSc | COO MD | Profile |
About Oncopeptides Management Performance
The success or failure of an entity such as Oncopeptides AB often depends on how effective the management is. Oncopeptides management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oncopeptides management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oncopeptides management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Oncopeptides AB , a pharmaceutical company, develops drugs for the treatment of cancer. The company was founded in 2000 and is headquartered in Stockholm, Sweden. Oncopeptides is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Oncopeptides' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncopeptides AB. Check Oncopeptides' Beneish M Score to see the likelihood of Oncopeptides' management manipulating its earnings.
Oncopeptides Workforce Analysis
Traditionally, organizations such as Oncopeptides use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oncopeptides within its industry.Oncopeptides Manpower Efficiency
Return on Oncopeptides Manpower
| Revenue Per Employee | 3M | |
| Revenue Per Executive | 14.8M | |
| Net Loss Per Employee | 35.8M | |
| Net Loss Per Executive | 178.8M |
Additional Tools for Oncopeptides Stock Analysis
When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.